← Back to Clinical Trials
Recruiting NCT05810571

NCT05810571 Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05810571
Status Recruiting
Phase
Sponsor Kocaeli University
Condition Renal Cell Carcinoma
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-10-24
Primary Completion 2027-01-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
preoperative remifentanil consumptionpostopeartive controlled anlagesia with morphine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-10-24 with a primary completion date of 2027-01-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

patients who will undergo elective open nephrectomy will be divided into three groups; the control (PCA), the erector spina plane block, and the quadratus lumborum block. After standard anesthesia induction and monitorization then Bispectral index monitoring will be applied to all patients. Anesthesia will be maintained using sevoflurane in a mixture of oxygen and air. Continuous remifentanil infusion will be used for analgesia. Then patient's numeric rating scales and morphine pca consumptions will be recorded for one day.

Eligibility Criteria

Inclusion Criteria: * ASA 1-3 * open nephrectomy elective patients * BMI\<35 Exclusion Criteria: * ASA 4-5-6 * Laparoscopic nephrectomy * infection at the block side * coagulation disorder * BMI\>35

Contact & Investigator

Central Contact

zehra ipek Arslan AYDIN, Professor

✉ zehraipek48@gmail.com

📞 00905325011339

Frequently Asked Questions

Who can join the NCT05810571 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Renal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05810571 currently recruiting?

Yes, NCT05810571 is actively recruiting participants. Contact the research team at zehraipek48@gmail.com for enrollment information.

Where is the NCT05810571 trial being conducted?

This trial is being conducted at İzmit, Turkey (Türkiye), Kocaeli, Turkey (Türkiye).

Who is sponsoring the NCT05810571 clinical trial?

NCT05810571 is sponsored by Kocaeli University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology